Literature DB >> 8137462

Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells.

A Colin de Verdière1, C Dubernet, F Nemati, M F Poupon, F Puisieux, P Couvreur.   

Abstract

Previous studies have clearly demonstrated that polyisobutylcyanoacrylate (PIBCA) doxorubicin-loaded nanoparticles (NS-Dox PIBCA) can overcome the resistance of P388/ADR cells. In the present paper, we found that overcoming multidrug resistance with the aid of doxorubicin (Dox) loaded onto these nanoparticles was associated with an increased intracellular drug content. Indeed, after a 6-h incubation period, the amount of cell-associated drug was 5 times higher when the cells were incubated with NS-Dox PIBCA as compared with free Dox. Further experiments, such as uptake studies in the presence of cytochalasin B or efflux studies, indicated a possible mechanism of nanoparticle/cell interaction. These results suggested that nanoparticles did not enter the cells by an endocytic process, in contrast to a previous hypothesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137462     DOI: 10.1007/bf00686509

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

Review 1.  The role of topoisomerase II in drug resistance.

Authors:  P De Isabella; G Capranico; F Zunino
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

2.  Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties.

Authors:  P Couvreur; B Kante; M Roland; P Guiot; P Bauduin; P Speiser
Journal:  J Pharm Pharmacol       Date:  1979-05       Impact factor: 3.765

Review 3.  P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins.

Authors:  P F Juranka; R L Zastawny; V Ling
Journal:  FASEB J       Date:  1989-12       Impact factor: 5.191

4.  A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.

Authors:  F Y Lee; J Sciandra; D W Siemann
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

5.  Immobilized adriamycin: a tool for separating cell surface from intracellular mechanisms.

Authors:  T R Tritton; G Yee; L B Wingard
Journal:  Fed Proc       Date:  1983-02

6.  The anticancer agent adriamycin can be actively cytotoxic without entering cells.

Authors:  T R Triton; G Yee
Journal:  Science       Date:  1982-07-16       Impact factor: 47.728

7.  Nanocapsules: a new type of lysosomotropic carrier.

Authors:  P Couvreur; P Tulkens; M Roland; A Trouet; P Speiser
Journal:  FEBS Lett       Date:  1977-12-15       Impact factor: 4.124

8.  Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.

Authors:  C Cuvier; L Roblot-Treupel; J M Millot; G Lizard; S Chevillard; M Manfait; P Couvreur; M F Poupon
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

9.  Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells.

Authors:  R Baurain; A Zenebergh; A Trouet
Journal:  J Chromatogr       Date:  1978-09-21

10.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

Authors:  C J Chen; J E Chin; K Ueda; D P Clark; I Pastan; M M Gottesman; I B Roninson
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

View more
  21 in total

Review 1.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

Review 2.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

3.  A nano-sized blending system comprising identical triblock copolymers with different hydrophobicity for fabrication of an anticancer drug nanovehicle with high stability and solubilizing capacity.

Authors:  Ngoc Ha Hoang; Taehoon Sim; Chaemin Lim; Thi Ngoc Le; Sang Myung Han; Eun Seong Lee; Yu Seok Youn; Kyung Taek Oh
Journal:  Int J Nanomedicine       Date:  2019-05-17

4.  Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  Nano Today       Date:  2013-06-01       Impact factor: 20.722

5.  A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution.

Authors:  Yilwoong Yi; Jae Hong Kim; Hye-Won Kang; Hun Seung Oh; Sung Wan Kim; Min Hyo Seo
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

6.  Gold nanorods mediated controlled release of doxorubicin: nano-needles for efficient drug delivery.

Authors:  Sunil Pandey; Ritu Shah; Ashmi Mewada; Mukeshchand Thakur; Goldie Oza; Madhuri Sharon
Journal:  J Mater Sci Mater Med       Date:  2013-03-23       Impact factor: 3.896

7.  Circumventing tumor resistance to chemotherapy by nanotechnology.

Authors:  Xing-Jie Liang; Chunying Chen; Yuliang Zhao; Paul C Wang
Journal:  Methods Mol Biol       Date:  2010

Review 8.  Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.

Authors:  P S Thakur; A M Khan; S Talegaonkar; F J Ahmad; Z Iqbal
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-26       Impact factor: 4.553

Review 9.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Authors:  Ameya R Kirtane; Stephen M Kalscheuer; Jayanth Panyam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-10       Impact factor: 15.470

Review 10.  Multifunctional nanoparticulate polyelectrolyte complexes.

Authors:  Sean M Hartig; Rachel R Greene; Jayasri DasGupta; Gianluca Carlesso; Mikhail M Dikov; Ales Prokop; Jeffrey M Davidson
Journal:  Pharm Res       Date:  2007-10-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.